Home » FDA Approves Cyltezo as Humira Biosimilar
FDA Approves Cyltezo as Humira Biosimilar
August 31, 2017
The FDA approved Boehringer Ingelheim’s Cyltezo (adalimumab-adbm), the second biosimilar to AbbVie’s Humira.
Cyltezo injection, 40 mg/0.8 mL is indicated for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Adult Crohn’s Disease, ulcerative colitis, and plaque psoriasis.
The agency approved Amjevita, Amgen’s Humira biosimilar, in September 2016.
Upcoming Events
-
21Oct